Abstract
RNA interference (RNAi) is a process of double-stranded RNA-dependent post-transciptional gene silencing that occurs mainly in the mRNA processing bodies (P-bodies) of cells. It has become the most powerful and widely used gene strategy for genetic analysis and molecular therapeutics, based on the highly specific and efficient silencing of target genes. The key challenge for achieving effective RNAi in vitro and in vivo is its delivery to the desired organs and into the target cells. The RNAi delivery systems can be either non-viral or viral vectors. The main candidate for RNAi as a therapeutical tool is the viral-based vectors, including retroviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses and herpes simplex virus-1 (HSV-1). There is a high potential for clinical use of RNAi in treatment of a wide variety of human diseases, including genetic disorders, infectious diseases and cancer. This paper reviews the designs of inducible, tissue specific, hybrid, oncolytic and high-throughput RNAi vectors based on plasmids or viruses, and discusses their specificity, efficiency and safety.
Keywords: RNAi, processing body, viral vectors, therapeutical design
Current Pharmaceutical Design
Title: The Design of Vectors for RNAi Delivery System
Volume: 14 Issue: 13
Author(s): Qi Zhao Wang, Ying Hui Lv, Yong Diao and Ruian Xu
Affiliation:
Keywords: RNAi, processing body, viral vectors, therapeutical design
Abstract: RNA interference (RNAi) is a process of double-stranded RNA-dependent post-transciptional gene silencing that occurs mainly in the mRNA processing bodies (P-bodies) of cells. It has become the most powerful and widely used gene strategy for genetic analysis and molecular therapeutics, based on the highly specific and efficient silencing of target genes. The key challenge for achieving effective RNAi in vitro and in vivo is its delivery to the desired organs and into the target cells. The RNAi delivery systems can be either non-viral or viral vectors. The main candidate for RNAi as a therapeutical tool is the viral-based vectors, including retroviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses and herpes simplex virus-1 (HSV-1). There is a high potential for clinical use of RNAi in treatment of a wide variety of human diseases, including genetic disorders, infectious diseases and cancer. This paper reviews the designs of inducible, tissue specific, hybrid, oncolytic and high-throughput RNAi vectors based on plasmids or viruses, and discusses their specificity, efficiency and safety.
Export Options
About this article
Cite this article as:
Wang Zhao Qi, Lv Hui Ying, Diao Yong and Xu Ruian, The Design of Vectors for RNAi Delivery System, Current Pharmaceutical Design 2008; 14 (13) . https://dx.doi.org/10.2174/138161208799316357
DOI https://dx.doi.org/10.2174/138161208799316357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Current Pharmaceutical Design The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM
Current Cancer Drug Targets Editorial (Thematic Issue: Emerging Concepts and Therapeutics Strategies for the Treatment of Brain Tumors)
Anti-Cancer Agents in Medicinal Chemistry MALDI Mass Spectrometry Imaging, from its Origins up to Today: The State of the Art
Combinatorial Chemistry & High Throughput Screening Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Hyaluronic Acid/Parecoxib-Loaded PLGA Microspheres for Therapy of Temporomandibular Disorders
Current Drug Delivery Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Graphene Family of Nanomaterials: Reviewing Advanced Applications in Drug delivery and Medicine
Current Drug Delivery